Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 104


Conditional survival estimates improve over time for patients with advanced melanoma: results from a population-based analysis.

Xing Y, Chang GJ, Hu CY, Askew RL, Ross MI, Gershenwald JE, Lee JE, Mansfield PF, Lucci A, Cormier JN.

Cancer. 2010 May 1;116(9):2234-41. doi: 10.1002/cncr.24966.


Conditional survival after surgical treatment of melanoma: an analysis of the Surveillance, Epidemiology, and End Results database.

Rueth NM, Groth SS, Tuttle TM, Virnig BA, Al-Refaie WB, Habermann EB.

Ann Surg Oncol. 2010 Jun;17(6):1662-8. doi: 10.1245/s10434-010-0965-8. Epub 2010 Feb 18.


Conditional survival estimates improve over 5 years for melanoma survivors with node-positive disease.

Bowles TL, Xing Y, Hu CY, Mungovan KS, Askew RL, Chang GJ, Gershenwald JE, Lee JE, Mansfield PF, Ross MI, Cormier JN.

Ann Surg Oncol. 2010 Aug;17(8):2015-23. doi: 10.1245/s10434-010-1051-y. Epub 2010 Apr 6.


An individualized conditional survival calculator for patients with rectal cancer.

Bowles TL, Hu CY, You NY, Skibber JM, Rodriguez-Bigas MA, Chang GJ.

Dis Colon Rectum. 2013 May;56(5):551-9. doi: 10.1097/DCR.0b013e31827bd287.


Melanoma survival in the United States, 1992 to 2005.

Pollack LA, Li J, Berkowitz Z, Weir HK, Wu XC, Ajani UA, Ekwueme DU, Li C, Pollack BP.

J Am Acad Dermatol. 2011 Nov;65(5 Suppl 1):S78-86. doi: 10.1016/j.jaad.2011.05.030.


Practical application of a calculator for conditional survival in colon cancer.

Chang GJ, Hu CY, Eng C, Skibber JM, Rodriguez-Bigas MA.

J Clin Oncol. 2009 Dec 10;27(35):5938-43. doi: 10.1200/JCO.2009.23.1860. Epub 2009 Oct 5.


Is sex an independent prognostic factor in cutaneous head and neck melanoma?

Arce PM, Camilon PR, Stokes WA, Nguyen SA, Lentsch EJ.

Laryngoscope. 2014 Jun;124(6):1363-7. doi: 10.1002/lary.24439. Epub 2013 Nov 7.


Survival differences between patients with scalp or neck melanoma and those with melanoma of other sites in the Surveillance, Epidemiology, and End Results (SEER) program.

Lachiewicz AM, Berwick M, Wiggins CL, Thomas NE.

Arch Dermatol. 2008 Apr;144(4):515-21. doi: 10.1001/archderm.144.4.515.


Implications of age and conditional survival estimates for patients with melanoma.

Banerjee M, Lao CD, Wancata LM, Muenz DG, Haymart MR, Wong SL.

Melanoma Res. 2016 Feb;26(1):77-82. doi: 10.1097/CMR.0000000000000213.


Conditional Survival in Anal Carcinoma Using the National Population-Based Survey of Epidemiology and End Results Database (1988-2012).

Kim E, Kim JS, Choi M, Thomas CR Jr.

Dis Colon Rectum. 2016 Apr;59(4):291-8. doi: 10.1097/DCR.0000000000000555.


Conditional survival among patients with adrenal cortical carcinoma determined using a national population-based surveillance, epidemiology, and end results registry.

Xiao WJ, Zhu Y, Dai B, Zhang HL, Shi GH, Shen YJ, Zhu YP, Ye DW.

Oncotarget. 2015 Dec 29;6(42):44955-62. doi: 10.18632/oncotarget.5831.


Primary genitourinary melanoma: Epidemiology and disease-specific survival in a large population-based cohort.

Sanchez A, Rodríguez D, Allard CB, Bechis SK, Sullivan RJ, Boeke CE, Kuppermann D, Cheng JS, Barrisford GW, Preston MA, Feldman AS.

Urol Oncol. 2016 Apr;34(4):166.e7-14. doi: 10.1016/j.urolonc.2015.11.009. Epub 2015 Dec 28.


Conditional survival in ovarian cancer: results from the SEER dataset 1988-2001.

Choi M, Fuller CD, Thomas CR Jr, Wang SJ.

Gynecol Oncol. 2008 May;109(2):203-9. doi: 10.1016/j.ygyno.2008.01.033. Epub 2008 Mar 7.


Ultrathin primary is a marker for worse prognosis in lymph node-positive cutaneous melanoma.

Bagaria SP, Ray PS, Joseph RW, Heckman MG, Rawal B, Gray RJ, Pockaj B, Wasif N.

Cancer. 2013 May 15;119(10):1860-7. doi: 10.1002/cncr.27985. Epub 2013 Feb 13.


Multivariate analysis of prognostic factors among 2,313 patients with stage III melanoma: comparison of nodal micrometastases versus macrometastases.

Balch CM, Gershenwald JE, Soong SJ, Thompson JF, Ding S, Byrd DR, Cascinelli N, Cochran AJ, Coit DG, Eggermont AM, Johnson T, Kirkwood JM, Leong SP, McMasters KM, Mihm MC Jr, Morton DL, Ross MI, Sondak VK.

J Clin Oncol. 2010 May 10;28(14):2452-9. doi: 10.1200/JCO.2009.27.1627. Epub 2010 Apr 5.


Primary cutaneous melanoma. Identification of prognostic groups and estimation of individual prognosis for 5093 patients.

Garbe C, Büttner P, Bertz J, Burg G, d'Hoedt B, Drepper H, Guggenmoos-Holzmann I, Lechner W, Lippold A, Orfanos CE, et al.

Cancer. 1995 May 15;75(10):2484-91.


Marital status independently predicts testis cancer survival--an analysis of the SEER database.

Abern MR, Dude AM, Coogan CL.

Urol Oncol. 2012 Jul-Aug;30(4):487-93. doi: 10.1016/j.urolonc.2010.03.005. Epub 2010 Sep 26.


Defining the role of CD2 in disease progression and overall survival among patients with completely resected stage-II to -III cutaneous melanoma.

Harcharik S, Bernardo S, Moskalenko M, Pan M, Sivendran M, Bell H, Hall LD, Castillo-Martín M, Fox K, Cordon-Cardo C, Chang R, Sivendran S, Phelps RG, Saenger Y.

J Am Acad Dermatol. 2014 Jun;70(6):1036-44. doi: 10.1016/j.jaad.2014.01.914. Epub 2014 Mar 31.


Follow-up recommendations for patients with American Joint Committee on Cancer Stages I-III malignant melanoma.

Poo-Hwu WJ, Ariyan S, Lamb L, Papac R, Zelterman D, Hu GL, Brown J, Fischer D, Bolognia J, Buzaid AC.

Cancer. 1999 Dec 1;86(11):2252-8.


Prognostic significance of spontaneous antibody responses against tumor-associated antigens in malignant melanoma patients.

Zörnig I, Halama N, Lorenzo Bermejo J, Ziegelmeier C, Dickes E, Migdoll A, Kaiser I, Waterboer T, Pawlita M, Grabe N, Ugurel S, Schadendorf D, Falk C, Eichmüller SB, Jäger D.

Int J Cancer. 2015 Jan 1;136(1):138-51. doi: 10.1002/ijc.28980. Epub 2014 May 28.

Supplemental Content

Support Center